Aflac Says Personal Info May Have Been Stolen in Cyberattack

Aflac AFL 0.53%increase; green up pointing triangle has been hit with a cyberattack that may have resulted in the theft of personal data related to the insurer's U.S. business.
Aflac on Friday said it identified suspicious activity on its U.S. network on June 12 and that it was able to stop the intrusion within hours.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

29 minutes ago

• Yahoo

Don't regulate us like radio, music streamer Spotify tells CRTC

OTTAWA — Music streamer Spotify says Canada's federal broadcast regulator shouldn't impose rules meant for radio on streaming services. Appearing before a CRTC hearing today, company representatives compared regulating Spotify like a radio station to treating Uber like a horse and buggy. In its written submission, Spotify argued the CRTC doesn't have the jurisdiction to extend rules governing commercial negotiations and disputes in the broadcast sector to online players. The CRTC is holding a hearing on market dynamics as part of its work to implement the Online Streaming Act, which updated broadcasting laws to capture online platforms. During previous hearings, large cable and broadcasting companies like Bell and Rogers called on the CRTC to loosen existing rules for traditional players. They're taking aim at regulations governing how cable channels must be packaged and disputes about carriage of cable channels. This report by The Canadian Press was first published June 20, 2025. Anja Karadeglija, The Canadian Press

Yahoo

34 minutes ago

• Yahoo

Eli Lilly (NYSE:LLY) Faces $7 Billion Lawsuit While Partnering With Innovative Biotech

Eli Lilly has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent developments, signaling strengthened research capabilities in precision immunotherapies and potentially bolstering investor confidence. Additionally, the company's legal entanglement with the lawsuit concerning Actos, following a class certification affirmation, highlights ongoing challenges in the pharmaceutical sector. The company's ongoing talks to acquire Verve Therapeutics also show its commitment to growing its gene-editing capabilities. These events have added weight to the broader market's trends. We've identified 2 warning signs for Eli Lilly (1 can't be ignored) that you should be aware of. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Recent developments at Eli Lilly, such as the RyboDyn Inc. collaboration, have potential implications for its strategic growth, particularly in precision immunotherapies. This aligns with the company's narrative of expanding capabilities in oncology and immunology, indicating possible enhancements in revenue and earnings forecasts over the long term. Additionally, as Eli Lilly progresses with Phase III trials, including those for orforglipron, the anticipated product approvals could bolster revenue avenues by tapping into high-demand markets like diabetes and obesity treatments. Over the past five years, Eli Lilly's total shareholder return was a very large 430.14%, demonstrating substantial long-term growth despite recent underperformance against the US Pharmaceuticals industry, which saw a 8.9% drop over the past year. This impressive five-year return provides context to the company's current position, underscoring a history of robust shareholder value creation. Given the ongoing acquisition talks with Verve Therapeutics and Eli Lilly's significant investment in both manufacturing and R&D, the outlook for future revenue and earnings remains optimistic. However, potential regulatory hurdles and pricing pressures, particularly in the U.S. market, highlight possible challenges. The shares, with a current price of US$775.12, are 21.0% below the analyst consensus target of US$981.63. This discount suggests room for growth, should the company meet or exceed the analyst expectations on revenue and earnings. Learn about Eli Lilly's future growth trajectory here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio

Yahoo

35 minutes ago

• Yahoo

Stellantis Evaluates Maserati's Future, Including Potential Sale -- Reuters

Stellantis (STLA, Financials) is weighing a possible sale of its luxury brand Maserati as part of a broader strategic review, according to a Reuters report citing two unnamed sources familiar with the matter. Warning! GuruFocus has detected 11 Warning Signs with STLA. The discussions reportedly began before newly appointed CEO Antonio Filosa officially takes the helm. Maserati's future is under review as Stellantis navigates a shrinking U.S. market, Chinese competition, and steep tariffs imposed by President Donald Trump on foreign-made cars and parts. Despite the internal review, a Stellantis spokesperson told Reuters that Maserati is not for sale. McKinsey declined to comment. Maserati's sales fell by over 50% last year to 11,300 units, with no new models currently scheduled for launch. A new business plan is expected once Filosa begins his tenure. Stellantis' board remains split on the brand's futuresome directors reportedly view Maserati as a reputational asset, while others believe it lacks viability for a sustainable relaunch. Analysts say streamlining Stellantis' 14-brand portfolio could improve profit margins. The company's shares have lost roughly two-thirds of their value since March 2024. Chinese automakers such as Chery could emerge as potential buyers, echoing earlier moves like Geely's acquisition of Volvo or SAIC's purchase of MG. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data